A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic

Project Details

StatusActive
Effective start/end date1/09/2330/09/26

Funding

  • AstraZeneca: A$45,000.00